Home > Resources > Company Profiles > K-V Pharmaceutical Company CL A

K-V Pharmaceutical Company CL A (KVA)

EMAIL
PRINT
SHARE
TEXT SIZE:
SHARE
Send a copy to me

Separate multiple email addresses (max 20) with commas.

0/1500
Marc S. Hermelin , CEO/Chairman of the Board/Director
Industry: Healthcare
OPEN
LAST
$
PREV CLOSE
CHANGE
VOLUME


Overview
News
People
Financials

Company Information

Marc S. Hermelin, CEO/Chairman of the Board/Director

2503 South Hanley Road

St. Louis, MO 63144

US Map it

Phone: (314) 645-6600

Fax: (314) 644-2419

www.kvpharma.com



Overview

The Company and its subsidiaries are engaged in the development, manufacture, acquisition, marketing and sale of technologically distinguished branded and generic/non-branded prescription pharmaceutical products.

Employees

Number of Employees: 1,590
Revenue per Employee: $332,337

Top Executives

David A. Van Vliet, Chief Administrative Officer
Paul T. Brady, Subsidiary President/Vice President, Divisional
Rita E. Bleser, President, Divisional

David S. Hermelin, Director/Divisional Vice President
Gregory J. Divis, Jr., President, Subsidiary
Gregory S. Bentley, General Counsel/Senior VP

Ronald J. Kanterman, CFO/Assistant Secretary/Vice President/Director/Treasurer
Raymond F. Chiostri, Vice President
Patricia K. McCullough, Subsidiary CEO

Richard H. Chibnall, Divisional Vice President/Chief Accounting Officer
Michael S. Anderson, Divisional Vice President

Board of Directors

Jonathon E. Killmer, Director
David A. Van Vliet, Chief Administrative Officer
Terry B. Hatfield, Director

David S. Hermelin, Director/Divisional Vice President
Jean M. Bellin, Director
Ronald J. Kanterman, CFO/Assistant Secretary/Vice President/Director/Treasurer

Financials

Quarterly
Annual

Income Statement 08/2008 06/2008 06/2008 03/2008
Sales 40.24 Mil. 47.87 Mil. 34.9 Mil. 34.4 Mil.
Gross Operating Profit 108.61 Mil. 105.12 Mil. 79.46 Mil. 74.58 Mil.
Operating Income before D & A (EBITDA) 30.89 Mil. 40 Mil. 14.49 Mil. 25.33 Mil.
Total Income Before Interest Expenses (EBIT) 22.24 Mil. 16.46 Mil. 12.05 Mil. 21.96 Mil.
Total Net Income 12.54 Mil. 9.32 Mil. 6.2 Mil. 12.08 Mil.
Basic EPS, Total 0.26 0.2 0.13 0.24
Diluted EPS, Total 0.23 0.16 0.12 0.21

BALANCE STATEMENT 08/2008 06/2008 06/2008 03/2008
Cash and Equivalents 94.17 Mil. 86.34 Mil. 80.76 Mil. 58.7 Mil.
Total Assets 383.95 Mil. 369.42 Mil. 446.44 Mil. 375.82 Mil.
Total Liabilities 71.52 Mil. 280.66 Mil. 248.05 Mil. 51.63 Mil.
Total Capitalization 732.04 Mil. 526.71 Mil. 411.86 Mil. 565.72 Mil.

Cash Flow 08/2008 06/2008 06/2008 03/2008
Net Cash From Continuing Operations 15.65 Mil. 122.36 Mil. 12.86 Mil. 23.26 Mil.
Net Cash From Investing Activities -7.7 Mil. -149.33 Mil. -14.49 Mil. -65.42 Mil.
Net Cash From Financing Activities -123 K. 30.74 Mil. -183 K. 166 K.
Net Change in Cash & Cash Equivalents 7.83 Mil. 3.77 Mil. -1.82 Mil. -42 Mil.

powered by Interactive Data

Income Statement 2008 2008 2006 2005
Sales 168.07 Mil. 129.68 Mil. 110.68 Mil. 98.43 Mil.
Gross Operating Profit 433.83 Mil. 313.94 Mil. 256.94 Mil. 205.06 Mil.
Operating Income before D & A (EBITDA) 178.99 Mil. 108.14 Mil. 87.66 Mil. 64.89 Mil.
Total Income Before Interest Expenses (EBIT) 142.02 Mil. 98.06 Mil. 44.96 Mil. 55.46 Mil.
Total Net Income 88.35 Mil. 58.09 Mil. 15.79 Mil. 33.27 Mil.
Basic EPS, Total 1.87 1.13 0.33 0.71
Diluted EPS, Total 1.55 0.98 0.31 0.63

BALANCE STATEMENT 2008 2008 2006 2005
Cash and Equivalents 86.34 Mil. 82.57 Mil. 100.71 Mil. 159.82 Mil.
Total Assets 369.42 Mil. 431.47 Mil. 347.99 Mil. 337.18 Mil.
Total Liabilities 280.66 Mil. 59.18 Mil. 36.76 Mil. 34.72 Mil.
Total Capitalization 526.71 Mil. 604.28 Mil. 550.59 Mil. 502.47 Mil.

Cash Flow 2008 2008 2006 2005
Net Cash From Continuing Operations 122.36 Mil. 57.14 Mil. 64.61 Mil. 49.03 Mil.
Net Cash From Investing Activities -149.33 Mil. -76.42 Mil. -156.46 Mil. -74.19 Mil.
Net Cash From Financing Activities 30.74 Mil. 1.15 Mil. 32.74 Mil. -6.6 Mil.
Net Change in Cash & Cash Equivalents 3.77 Mil. -18.13 Mil. -59.12 Mil. -31.76 Mil.

powered by Interactive Data







Related Companies by Market Cap
Company Name
Price
Change
Market Cap
Nektar Therapeutics, Inc.
672.04 Mil.
Alkermes, Incorporated
1.39 Bil.
Noven Pharmaceuticals, Inc.
331.7 Mil.
K-V Pharmaceutical Company CL B
326.67 Mil.

Company Profile Change Request

The data provided in our company profiles comes from third party information providers.

Also in Portfolio.com
Most Read
Most Emailed
Recently Commented